Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia
Author:
Affiliation:
1. Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital Oxford University Hospitals NHS Foundation Trust Oxford UK
Publisher
Wiley
Subject
Hematology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13837
Reference7 articles.
1. Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group
2. Genetic characterization of B‐cell prolymphocytic leukemia: a prognostic model involving MYC and TP53;Chapiro E;Blood,2019
3. Idelalisib‐rituximab induces durable remissions inTP53disrupted B‐PLL but results in significant toxicity: updated results of the UK‐wide compassionate use programme
4. Venetoclax is an option in B‐cell prolymphocytic leukaemia following progression on B‐cell receptor pathway inhibitors
5. Initial treatment of B‐cell prolymphocytic leukemia with ibrutinib
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prolymphocytic Leukaemia: an Update on Biology and Treatment;Current Oncology Reports;2024-01-02
2. B-cell prolymphocytic leukemia with P53 abnormalities successfully treated with bendamustine and rituximab: a report of three cases;Translational Cancer Research;2023-07
3. Idelalisib/rituximab;Reactions Weekly;2023-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3